Top Markets
#1 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +585.95%
#2 Phala Phala +86.06%
#3 Bitway Bitway +35.59%
#4 龙虾 (Lobster) 龙虾 (Lobster) +27.08%
#5 Backpack Backpack +25.83%
#6 ARK ARK +24.61%
#7 Mubarak Mubarak +24.07%
#8 Aerodrome Finance Aerodrome Finance +23.48%
#9 APEX APEX +21.77%
#10 The Black Bull The Black Bull +20.57%
Coin of the day
Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain)
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Clasificación en acciones #36735
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to... Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Precio por acción
$0.2483
Última sincronización: 2026-07-31
Capitalización bursátil
$2.30M
Cambio (1 día)
-3.39%
Cambio (1 año)
-89.01%
País
US
Comercio Ensysce Biosciences, Inc. (ENSC)

Categoría

Healthcare
Ratio P/S de Ensysce Biosciences, Inc. (ENSC)
Ratio P/S al September 2026 TTM: 6.35
Según los informes financieros más recientes y el precio de las acciones de Ensysce Biosciences, Inc., el ratio P/S actual (TTM) es 6.35. Al final de 2023, el ratio P/S era 16.14.
Historial del ratio P/S de Ensysce Biosciences, Inc. desde 2017 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
2026 (TTM) 6.35 132.71%
2024 2.73 -83.08%
2023 16.14 67.59%
2022 9.63 -97.61%
2021 402.60 -99.21%
2020 50.77K -60.81%
2019 129.53K 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.44 64.40%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
26.12 311.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.01 89.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.76 -40.89%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH